SGLT2抑制剂与急性肾损伤后长期结局
这项多中心随机对照试验纳入200例严重AKI幸存者,比较恩格列净10 mg/d与安慰剂治疗1年对MAKE365的影响。结果显示两组MAKE365发生率无显著差异(35% vs 36%,P=0.82),但恩格列净组复发性AKI发生率显著降低(34 vs 66/100人年,IRR 0.51,95%CI 0.31-0.84,P=0.008)。
要点
- 恩格列净未降低AKI后1年MAKE365复合终点。
- 恩格列净显著减少复发性AKI发生率。
- 研究人群为透析非依赖且eGFR≥20的严重AKI幸存者。
核心结论
- 恩格列净未能减少AKI后1年MAKE365,但显示出减少复发性AKI的潜在获益。
研究设计与样本
- 多中心随机对照试验,纳入3家三级医院的严重AKI幸存者,随机接受恩格列净10 mg/d或安慰剂治疗1年。
- 共纳入200例参与者,恩格列净组98例,安慰剂组102例;AKI 3期占主导,两组分别有30%和23%需要肾脏替代治疗。
主要发现
- 改良意向性治疗分析显示,MAKE365在恩格列净组发生率为35%,安慰剂组为36%(P=0.82)。
- 恩格列净组复发性AKI发生率为34/100人年,安慰剂组为66/100人年(IRR 0.51,95%CI 0.31-0.84,P=0.008)。
关键数值与推荐
- 纳入标准:严重AKI幸存者,透析非依赖,eGFR≥20 ml/min/1.73 m2。
- 主要终点MAKE365定义为持续性肾功能不全(eGFR持续下降≥25%或血清肌酐较基线升高≥200%)、需要长期透析或AKI后1年内死亡。
临床怎么用
- 对于严重AKI幸存者,恩格列净可能有助于减少复发性AKI,但未改善MAKE365复合终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Currently, there is no specific treatment for post-acute kidney injury (AKI) survivors, one of the highest risk groups of the renal and nonrenal adverse long-term outcomes. This study aimed to determine whether the sodium-glucose cotransporter-2 inhibitor (SGLT2i) can decrease 1-year major adverse kidney events (MAKE365) in post-AKI setting. METHODS: Multicenter randomized controlled trial, involving severe AKI survivors from 3 tertiary care hospitals, who were dialysis independent, and had an estimated glomerular filtration rate (eGFR) ≥ 20 ml/min per 1.73 m2. The participants were randomized to receive empagliflozin 10 mg/d or matching placebo for 1 year after the incident AKI. The primary outcome was MAKE365, defined as a composite of persistent kidney dysfunction (a sustained decrease in eGFR ≥ 25% or increase in serum creatinine ≥ 200% of baseline), the need for long-term dialysis, or death at 1 year after the incident of AKI. RESULTS: A total of 200 participants were included in this study, 98 patients in empagliflozin group and 102 patients in placebo group; AKI stage 3 was predominant, with renal replacement therapy required for 30% and 23% of patients in each group, respectively. On modified intention-to-treat analysis, MAKE365 occurred in 35% in the empagliflozin group and 36% in the placebo group (P = 0.82). The incident rate ratio indicated a significant reduction in recurrent AKI in the empagliflozin group (34 vs. 66 per 100 person-years, respectively; incident rate ratio: 0.51, 95% confidence interval [CI]: 0.31-0.84; P = 0.008). CONCLUSION: Empagliflozin could not show reduction in MAKE365 but showed potential benefits in reducing recurrent AKI.
引用
- Wannakittirat A, Nimkietkajorn V, Thanapongsathorn P, et al. SGLT2 Inhibitors and Long-Term Outcomes After AKI. Kidney Int Rep. 2025. PMID: 41684789. doi:10.1016/j.ekir.2025.103752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。